Platinum‐Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future

• Published in: The oncologist (Dayton, Ohio) Vol. 20; no. 4; pp. 411 - 432
• Main Authors: Avan, Abolfazl, Postma, Tjeerd J., Ceresa, Cecilia, Avan, Amir, Cavaletti, Guido, Giovannetti, Elisa, Peters, Godefridus J.
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.04.2015
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Humans; Neuro-Oncology; Neuroprotective Agents - pharmacology; Neurotoxicity; Neurotoxicity Syndromes - diagnosis; Neurotoxicity Syndromes - etiology; Pathogenesis; Pharmacogenetics; Platinum; Platinum Compounds - adverse effects; Platinum Compounds - therapeutic use; Polymorphism; Polymorphism, Genetic; Prevention; Prevention; Neurotoxicity; Models; Pathogenesis; Platinum; Polymorphism
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2014-0044

Neurotoxicity is a burdensome side effect of platinum‐based chemotherapy that prevents administration of the full efficacious dosage and often leads to treatment withdrawal. Peripheral sensory neurotoxicity varies from paresthesia in fingers to ataxic gait, which might be transient or irreversible. Because the number of patients being treated with these neurotoxic agents is still increasing, the need for understanding the pathogenesis of this dramatic side effect is critical. Platinum derivatives, such as cisplatin and carboplatin, harm mainly peripheral nerves and dorsal root ganglia neurons, possibly because of progressive DNA‐adduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal‐regulated kinase 1/2, c‐Jun N‐terminal kinase/stress‐activated protein kinase, and p38 mitogen‐activated protein kinass), which finally mediate apoptosis. Oxaliplatin, with a completely different pharmacokinetic profile, may also alter calcium‐sensitive voltage‐gated sodium channel kinetics through a calcium ion immobilization by oxalate residue as a calcium chelator and cause acute neurotoxicity. Polymorphisms in several genes, such as voltage‐gated sodium channel genes or genes affecting the activity of pivotal metal transporters (e.g., organic cation transporters, organic cation/carnitine transporters, and some metal transporters, such as the copper transporters, and multidrug resistance‐associated proteins), can also influence drug neurotoxicity and treatment response. However, most pharmacogenetics studies need to be elucidated by robust evidence. There are supportive reports about the effectiveness of several neuroprotective agents (e.g., vitamin E, glutathione, amifostine, xaliproden, and venlafaxine), but dose adjustment and/or drug withdrawal seem to be the most frequently used methods in the management of platinum‐induced peripheral neurotoxicity. To develop alternative options in the treatment of platinum‐induced neuropathy, studies on in vitro models and appropriate trials planning should be integrated into the future design of neuroprotective strategies to find the best patient‐oriented solution. This review summarizes preclinical and clinical evidence of pathogenesis and pathophysiology of platinum‐induced peripheral neurotoxicity, as well as available evidence of neuroprotective and therapeutic strategies. These data may help to develop alternative options in the treatment of platinum‐induced neuropathy, studies on in vitro models, and appropriate trials planning to find the best patient‐oriented solution.